|
SI1283839T1
(https=)
*
|
2000-05-26 |
2005-08-31 |
Schering Corp |
|
|
EP1425017A1
(en)
*
|
2001-09-13 |
2004-06-09 |
Schering Corporation |
Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
|
|
JP4545437B2
(ja)
|
2001-10-15 |
2010-09-15 |
シェーリング コーポレイション |
アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン
|
|
FR2832405B1
(fr)
*
|
2001-11-19 |
2004-12-10 |
Sanofi Synthelabo |
Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
|
|
PE20030739A1
(es)
|
2001-11-30 |
2003-08-28 |
Schering Corp |
Antagonistas del receptor de adenosina a2a
|
|
CA2468649C
(en)
*
|
2001-11-30 |
2009-03-10 |
Schering Corporation |
Adenosine a2a receptor antagonists
|
|
ES2283625T3
(es)
|
2001-11-30 |
2007-11-01 |
Schering Corporation |
Antagonistas del receptopr a2a de adenosina de (1,2,4)-triazol biciclicos.
|
|
CN101543497A
(zh)
|
2002-01-28 |
2009-09-30 |
协和发酵工业株式会社 |
治疗运动疾病患者的方法
|
|
IL160133A0
(en)
*
|
2002-05-30 |
2004-06-20 |
King Pharmaceuticals Res & Dev |
Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
|
|
US20060106040A1
(en)
*
|
2002-12-19 |
2006-05-18 |
Michael Grzelak |
Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
|
|
JP2006514697A
(ja)
*
|
2002-12-19 |
2006-05-11 |
シェーリング コーポレイション |
アデノシンＡ２ａレセプターアンタゴニストの使用
|
|
US20070010522A1
(en)
|
2003-04-09 |
2007-01-11 |
Chi Vu |
Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
|
|
CL2004000847A1
(es)
*
|
2003-04-23 |
2005-03-11 |
Schering Corp |
Compuestos derivados de 2-alquinil o 2-alquenil-5amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-]pirimidina; composicion farmaceutica, y uso en el tratamiento de enfermedades del sistema nervioso central o un accidente cerebrovascular tal como depresion,
|
|
ATE481101T1
(de)
*
|
2003-06-10 |
2010-10-15 |
Kyowa Hakko Kirin Co Ltd |
Verfahren zur behandlung von angstzuständen
|
|
EP1636187A1
(en)
*
|
2003-06-12 |
2006-03-22 |
Novo Nordisk A/S |
Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase
|
|
JP4800216B2
(ja)
*
|
2003-10-24 |
2011-10-26 |
エグゼリクシス， インコーポレイテッド |
ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法
|
|
CN1898246B
(zh)
|
2003-10-28 |
2010-10-27 |
先灵公司 |
制备取代的5-氨基-吡唑并[4，3-e]-1，2，4-三唑并[1，5-c]嘧啶的方法
|
|
WO2005054245A2
(en)
*
|
2003-12-01 |
2005-06-16 |
Schering Corporation |
Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
|
|
WO2005060981A2
(en)
*
|
2003-12-19 |
2005-07-07 |
Schering Corporation |
Pharmaceutical compositions
|
|
EP1745047B1
(en)
*
|
2004-04-21 |
2010-03-24 |
Schering Corporation |
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists
|
|
EP1902716A4
(en)
*
|
2005-06-07 |
2009-05-13 |
Kyowa Hakko Kirin Co Ltd |
PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR MOTOR TROUBLESHOOTING
|
|
ATE538123T1
(de)
*
|
2005-09-19 |
2012-01-15 |
Schering Corp |
2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
|
|
AR056080A1
(es)
|
2005-09-23 |
2007-09-19 |
Schering Corp |
7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
|
|
ES2273599B1
(es)
|
2005-10-14 |
2008-06-01 |
Universidad De Barcelona |
Compuestos para el tratamiento de la fibrilacion auricular.
|
|
JP5539717B2
(ja)
*
|
2006-07-14 |
2014-07-02 |
塩野義製薬株式会社 |
オキシム化合物およびその使用
|
|
TW200840566A
(en)
*
|
2006-12-22 |
2008-10-16 |
Esteve Labor Dr |
Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
|
|
US7691869B2
(en)
|
2007-03-30 |
2010-04-06 |
King Pharmaceuticals Research And Development, Inc. |
Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
|
|
US8669260B2
(en)
*
|
2008-02-29 |
2014-03-11 |
Albert Einstein College Of Medicine Of Yeshiva University |
Ketoconazole-derivative antagonist of human pregnane X receptor and uses thereof
|
|
EP2262811B1
(en)
|
2008-03-04 |
2016-04-27 |
Merck Sharp & Dohme Corp. |
1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e]-1,2,4-triazolo [4,3-c]pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
|
|
CN102014959B
(zh)
|
2008-03-10 |
2016-01-20 |
康奈尔大学 |
血脑屏障通透性的调节
|
|
TWI473614B
(zh)
*
|
2008-05-29 |
2015-02-21 |
Kyowa Hakko Kirin Co Ltd |
Anti-analgesic inhibitors
|
|
NZ590793A
(en)
*
|
2008-07-23 |
2012-07-27 |
Kyowa Hakko Kirin Co Ltd |
Therapeutic agent for migraine
|
|
US20100093702A1
(en)
*
|
2008-10-13 |
2010-04-15 |
Barbay J Kent |
METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
|
|
WO2010078430A1
(en)
|
2008-12-30 |
2010-07-08 |
Arqule, Inc. |
Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
|
|
US20120053182A1
(en)
|
2009-01-20 |
2012-03-01 |
Schering Corporation |
Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease
|
|
WO2010084160A1
(en)
|
2009-01-21 |
2010-07-29 |
Oryzon Genomics S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
JP5765239B2
(ja)
|
2009-03-13 |
2015-08-19 |
アドヴィナス・セラピューティックス・リミテッド |
置換縮合ピリミジン化合物
|
|
TW201100427A
(en)
|
2009-03-31 |
2011-01-01 |
Arqule Inc |
Substituted heterocyclic compounds
|
|
US8537177B2
(en)
*
|
2009-06-15 |
2013-09-17 |
Marvell World Trade Ltd. |
System and methods for gamut bounded saturation adaptive color enhancement
|
|
US8598343B2
(en)
|
2009-08-07 |
2013-12-03 |
Merck Sharp & Dohme Corp. |
Process for preparing a 2-alkynyl substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
|
|
RU2602814C2
(ru)
|
2009-09-25 |
2016-11-20 |
Оризон Дженомикс С.А. |
Лизинспецифические ингибиторы деметилазы-1 и их применение
|
|
US8946296B2
(en)
|
2009-10-09 |
2015-02-03 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
|
|
WO2011101861A1
(en)
|
2010-01-29 |
2011-08-25 |
Msn Laboratories Limited |
Process for preparation of dpp-iv inhibitors
|
|
WO2011106573A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
|
WO2011106574A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
|
RS55348B1
(sr)
|
2010-04-19 |
2017-03-31 |
Oryzon Gnomics S A |
Inhibitori lizin specifične demetilaze-1 i njihova upotreba
|
|
EP2598480B1
(en)
|
2010-07-29 |
2019-04-24 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as lsd1 inhibitors
|
|
WO2012013728A1
(en)
|
2010-07-29 |
2012-02-02 |
Oryzon Genomics S.A. |
Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
|
|
CN103261202B
(zh)
*
|
2010-09-24 |
2016-01-20 |
阿迪维纳斯疗法有限公司 |
作为腺苷受体拮抗剂的稠合三环化合物
|
|
US9061966B2
(en)
|
2010-10-08 |
2015-06-23 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
WO2012107498A1
(en)
|
2011-02-08 |
2012-08-16 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
WO2012129381A1
(en)
*
|
2011-03-22 |
2012-09-27 |
Concert Pharmaceuticals Inc. |
Deuterated preladenant
|
|
WO2012127472A1
(en)
*
|
2011-03-22 |
2012-09-27 |
Mapi Pharma Ltd. |
Process and intermediates for the preparation of preladenant and related compounds
|
|
WO2013024474A1
(en)
*
|
2011-08-18 |
2013-02-21 |
Mapi Phrarma Ltd. |
Polymorphs of preladenant
|
|
RU2668952C2
(ru)
|
2011-10-20 |
2018-10-05 |
Оризон Дженомикс, С.А. |
(гетеро)арилциклопропиламины в качестве ингибиторов lsd1
|
|
MX356344B
(es)
|
2011-10-20 |
2018-05-23 |
Oryzon Genomics Sa |
Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1.
|
|
WO2014071512A1
(en)
*
|
2012-11-06 |
2014-05-15 |
Universite Laval |
Combination therapy and methods for the treatment of respiratory diseases
|
|
WO2014101120A1
(en)
*
|
2012-12-28 |
2014-07-03 |
Merck Sharp & Dohme Corp. |
Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
|
|
CA2967944C
(en)
|
2014-11-18 |
2020-11-17 |
Merck Sharp & Dohme Corp. |
Aminopyrazine compounds with a2a antagonist properties
|
|
US10138212B2
(en)
|
2015-02-06 |
2018-11-27 |
Merck Sharp & Dohme Corp. |
Aminoquinazoline compounds as A2A antagonist
|
|
US10688082B2
(en)
|
2015-06-11 |
2020-06-23 |
Merck Sharp & Dohme Corp. |
Aminopyrazine compounds with A2A antagonist properties
|
|
WO2017008205A1
(en)
|
2015-07-10 |
2017-01-19 |
Merck Sharp & Dohme Corp. |
Substituted aminoquinazoline compounds as a2a antagonist
|
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
|
DK3601296T3
(da)
*
|
2017-03-30 |
2022-08-29 |
iTeos Belgium SA |
2-oxo-thiazolderivater som a2a-inhibitorer og forbindelser til anvendelse ved behandling af cancere
|
|
WO2018178338A1
(en)
*
|
2017-03-30 |
2018-10-04 |
Iteos Therapeutics |
2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
|
|
EP3723754A4
(en)
|
2017-12-13 |
2021-05-19 |
Merck Sharp & Dohme Corp. |
IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST
|
|
CA3087655A1
(en)
*
|
2018-01-04 |
2019-07-11 |
Impetis Biosciences Ltd. |
Tricyclic compounds, compositions and medicinal applications thereof
|
|
BR122023024273A2
(pt)
|
2018-02-27 |
2024-02-20 |
Incyte Corporation |
Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
|
|
CN108276345A
(zh)
*
|
2018-03-22 |
2018-07-13 |
重庆奥舍生物化工有限公司 |
一种药物中间体嘧啶-5-甲醛的制备方法
|
|
MX2020010618A
(es)
*
|
2018-04-08 |
2020-11-12 |
Beigene Ltd |
Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
|
|
WO2019222677A1
(en)
|
2018-05-18 |
2019-11-21 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
|
CN108864114B
(zh)
*
|
2018-06-04 |
2020-11-06 |
应世生物科技(南京)有限公司 |
选择性a2a受体拮抗剂
|
|
GEP20237548B
(en)
|
2018-07-05 |
2023-10-10 |
Incyte Corp |
Fused pyrazine derivatives as a2a /a2b inhibitors
|
|
CN110742893B
(zh)
*
|
2018-07-23 |
2024-04-05 |
百济神州(北京)生物科技有限公司 |
A2a受体拮抗剂治疗癌症的方法
|
|
TW202039496A
(zh)
|
2018-11-30 |
2020-11-01 |
美商默沙東藥廠 |
做為腺苷受體拮抗劑之9-經取代胺基三唑喹唑啉衍生物、醫藥組合物及其用途
|
|
CA3124088A1
(en)
|
2018-12-20 |
2020-06-25 |
Incyte Corporation |
Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
WO2020227156A1
(en)
*
|
2019-05-03 |
2020-11-12 |
Nektar Therapeutics |
Adenosine 2 receptor antagonists
|
|
DE102019116986A1
(de)
|
2019-06-24 |
2020-12-24 |
Helmholtz-Zentrum Dresden-Rossendorf E. V. |
Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
|
|
CN114667287A
(zh)
*
|
2019-07-17 |
2022-06-24 |
泰昂治疗公司 |
腺苷a2a受体拮抗剂及其用途
|
|
CN112592346B
(zh)
|
2019-07-30 |
2022-04-26 |
厦门宝太生物科技股份有限公司 |
一种a2a和/或a2b抑制剂中间体的制备方法
|
|
CN111825698B
(zh)
|
2019-07-30 |
2021-10-15 |
杭州阿诺生物医药科技有限公司 |
腺苷受体拮抗剂
|
|
CN111072675A
(zh)
*
|
2019-12-12 |
2020-04-28 |
广东东阳光药业有限公司 |
含氮稠合三环衍生物及其用途
|
|
CN113773327B
(zh)
*
|
2021-09-13 |
2022-07-15 |
八叶草健康产业研究院(厦门)有限公司 |
一种吡唑并嘧啶并三唑环类化合物的制备方法
|
|
CN117946123A
(zh)
*
|
2024-01-26 |
2024-04-30 |
北京脑重大疾病研究院 |
放射性三氮唑并嘧啶基衍生物及其制备方法和应用
|
|
CN118812539B
(zh)
*
|
2024-06-19 |
2025-11-28 |
苏州大学 |
一种5-氨基三唑并嘧啶衍生物及其制备方法
|
|
CN118812544A
(zh)
*
|
2024-06-19 |
2024-10-22 |
厦门大学 |
一种腺苷a2ar靶向小分子化合物、核素标记探针及其制备方法、应用和药物组合物
|